Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial

O'Donoghue, Michelle; Fazio, Sergio; Giugliano, Robert; Stroes, Erik; Kanevsky, Estella; Gouni-Berthold, Ioanna; Im, KyungAh; Pineda, Armando; Wasserman, Scott; Ceska, Richard; Ezhov, Marat; Jukema, J.; Jensen, Henrik; TOKGÖZOĞLU, SADBERK; Mach, Francois; Huber, Kurt; Sever, Peter; Keech, Anthony; Pedersen, Terje; Sabatine, Marc

doi:10.1161/circulationaha.118.037184

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial

Atıf İçin Kopyala

O'Donoghue M. L. , Fazio S., Giugliano R. P. , Stroes E. S. G. , Kanevsky E., Gouni-Berthold I., ...Daha Fazla

CIRCULATION, cilt.139, sa.12, ss.1483-1492, 2019 (SCI İndekslerine Giren Dergi)

Cilt numarası: 139 Konu: 12
Basım Tarihi: 2019
Doi Numarası: 10.1161/circulationaha.118.037184
Dergi Adı: CIRCULATION
Sayfa Sayıları: ss.1483-1492

Özet

BACKGROUND: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration. However, the relationship between Lp(a) levels, PCSK9 inhibition, and cardiovascular risk reduction remains undefined.